April 06, 2021
Article
Some drugs commonly used for psoriasis can increase the risk of cardiovascular diseases, whereas other treatments can reduce the risk.
January 08, 2021
According to the study authors, this could lead to finding the exact molecular trigger and gives hope for developing a targeted PsA treatment in the future.
October 01, 2020
The FDA has approved golimumab for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.
June 28, 2020
A virtual symposium held in conjunction with the Asembia Specialty Pharmacy Summit focused on psoriatic arthritis.
January 09, 2020
Secukinumab provided early and sustained resolution of enthesitis in patients with psoriatic arthritis based on post hoc analysis pooled data from the FUTURE trial.
December 03, 2019
It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.
September 20, 2019
Top news of the day across the health care landscape.
July 24, 2019
Top news of the day from across the health care landscape.
July 03, 2019
July 01, 2019
Treatment with secukinumab (Cosentyx, Novartis) inhibited radiographic progression in most patients with psoriatic arthritis over 2 years in a phase 3 trial.
